OMEZA is a leader in wound healing, with the first drug-device product that reduces biofilm formation and inhibits microbial growth without the risk of developing antimicrobial resistance. The company is already pursuing multiple commercialization strategies with Medicare, the Veteran’s Affairs (VA), and the U.S. Department of Defense. Check out the prior videos on commercialization in case you missed it!
OMEZA currently has the reimbursement code A2014 which can be added to any wound care procedure. The company is building upon clinical evidence with peer-reviewed publications to go to the private payor community, which they expect to have completed in the 4th quarter of 2024.